PRESS RELEASE published on 06/30/2025 at 21:33, 5 months 4 days ago Sanofi: Disclosure of trading in own shares
BRIEF published on 06/30/2025 at 07:35, 5 months 5 days ago Sanofi Releases Q2 2025 Aide Mémoire Forward-looking Statements Investor Information Financial Modeling Aide Mémoire Sanofi Q2 2025
PRESS RELEASE published on 06/30/2025 at 07:30, 5 months 5 days ago Press release: Availability of the Q2 2025 Aide mémoire Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF published on 06/25/2025 at 07:05, 5 months 10 days ago Riliprubart Granted Orphan Drug Designation in the United States FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE published on 06/25/2025 at 07:00, 5 months 10 days ago Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF published on 06/23/2025 at 07:05, 5 months 12 days ago Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE published on 06/23/2025 at 07:00, 5 months 12 days ago Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF published on 06/20/2025 at 07:05, 5 months 15 days ago FDA Approves Dupixent for Bullous Pemphigoid Treatment FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
PRESS RELEASE published on 06/20/2025 at 07:00, 5 months 15 days ago Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
BRIEF published on 06/17/2025 at 13:45, 5 months 17 days ago Sanofi Successfully Prices €1.5 Billion Bond Issue Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note
Published on 12/05/2025 at 02:35, 10 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:00, 27 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 27 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 22 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 27 minutes ago CGTN:Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 27 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 08:45, 4 hours 42 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health